Physician Views: What impact from biosimilar Lucentis?

With the first biosimilar version of Novartis and Roche’s Lucentis now approved in both Europe and the US we are snap-polling ophthalmologists in both regions to ascertain how it may – or may not – be used when it launches in the next 12-18 months.

Specifically we are asking them…

Which of Lucentis, Eylea, Beovu or off-label Avastin do you consider to be the best overall wet AMD/DME therapy?

Do you anticipate proactively using biosimilar Lucentis once it becomes available?

Which of factors would you anticipate reducing or preventing your use of biosimilar Lucentis?

If you expect to prescribe biosimilar Lucentis which product(s) would you anticipate it being at the expense of?

Looking further ahead would you anticipate proactively using a biosimilar version of Eylea once it becomes available (likely in 2024)?

Poll results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here

To read more Physician Views articles, click here.

Reference Articles